GLOBAL INHALABLE DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Inhalable Drugs Market, By Drug Class (Inhaled Corticosteroids, Leukotriene modifiers, Long-acting beta agonists (LABAs), Long-acting muscarinic antagonists (LAMAs), Others), By Product Type (Aerosol, Dry powder Formulation, Spray, Others), By Application (Respiratory Diseases, Non-respiratory Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Inhalable Drugs Market- Recent Developments

Product Approval and Launch

On July 31, 2023 Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P., a pharmaceutical contract development and manufacturing organization, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca's Symbicort. Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
In September 2020, GlaxoSmithKline plc. announced that the U.S. Food and Drug Administration (FDA) had approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm. The U.S. FDA-approved strength for both chronic obstructive pulmonary disease and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate / umeclidinium / vilanterol 200/62.5/25mcg.

Research and Development Activities by the Market Players

On November 27, 2023, Sanofi, a pharmaceutical company, announced that Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating U.S. Food and Drug Administration submission and confirming potential to become first approved biologic for this serious disease
In November 2022, PT027 had been recommended by the U.S.FDA Advisory Committee as new rescue treatment for asthma. T027 is a potential first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the U.S. It is being developed by AstraZeneca, a pharmaceutical company and Avillion, a global drug development company.